The authors analyse which is the best approach in diagnosing and staging prostatic cancer. They tackle the problem of screening by analysing current methods, concluding that PSA measurement is the best. It is impossible not to consider a combination of prognostic factors (Gleason score, PSA, clinical staging) when choosing pre-operative staging methods.
ParkerS.TongT.BoldenS.WingoP.: Cancer Statistics 1996. CA Cancer J. Clin., 65: 5–27, 1996.
2.
BoyleP.: Prostate cancer epidemiology: an overview. Urologia Pratica, 2: 60–71, 1975.
3.
ProrokP.C.ConnorR.J.BakerS.G.: Statistical considerations in cancer screening programs. Urol. Clin. North Am., 17: 699–708, 1990.
4.
FranksL.M.: Latent carcinoma of the prostate. J. Pathol. Bacteriol., 68: 603–616, 1954.
5.
MettlinC.LeeF.DragoJ.MurphyG.P. and the investigators of the American Cancer Society National Prostate Cancer Detection Project. The American Cancer Society National Prostate Cancer Detection Project: Findings on the detection of early prostate cancer in 2425 men. Cancer, 67: 2949–2958, 1991.
6.
ChodakG.W.KellerP.ShoienbergerH.W.: Assessment of screening for prostate cancer using the digital rectal examination. J. Urol., 141: 1136–1138, 1989.
7.
OesterlingJ.E.: Prostate specific antigen: a critical assessment of the most useful tumour marker for adenocarcinoma of the prostate. J. Urol., 145: 907–923, 1991.
8.
CoonerW.H.: Prostate specific antigen, digital rectal examination, and transrectal ultrasonic examination of the prostate in prostate cancer detection. Monogr. Urol., 12: 3–13, 1991.
9.
CatalonaW.J.SmithD.S.RatlifT.L.DoddsK.M.CoplenD.E.YuanJ.J.J.PetrosJ.A.AndrioleG.L.: Measurement of the prostate specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med., 324: 1156–1161, 1991.
10.
WatanabeH.SaitohM.MishinaT.IgariD.IanattashiY.HaradaK.HisamichiS.: Mass screening program for prostatic disease with transrectal ultrasonotomography. J. Urol., 117: 746–748, 1977.
11.
LeeF.LittrupP.J.Torp-PendersenS.T.MettlinC.MettughT.A.GrayJ.M.KumasahaG.H.McLearyR.D.: Prostate cancer: comparison of transrectal US and digital rectal examination in screening. Radiology, 168: 389–394, 1988.
12.
OesterlingJ.E.: Using prostate specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology, 46: 23–26, 1995.
13.
BazinetM.MeshrefA.TrudelC.AronsonS.PeloquinF.NachabeM.BeginL.ElhilaliM.: Prospective evaluation of prostate specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology, 43; 44–51, 1994.
14.
RichieJ.P.: Screening for prostate: the horns of a dilemma. Educational Book American Society of Oncology by American Society of Clinical Oncology, 125–127, 1996.
15.
WalshP.C.Buchanan BradyJ.: Hereditary prostate. Educational Book American Society of Oncology by American Society of Clinical Oncology, 366–372, 1996.
16.
PartinA.W.CarterH.B.ChanD.W.EpsteinJ.I.OesterlingJ.E.RockR.C.WeberJ.P.WalshP.C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumour differentiation, tumour volume and benign hyperplasia. J. Urol., 143: 747–752, 1990.
17.
NarayanP.FournierG.GajendranV.LeidichR.LoR.WolfJ.S.JacobG.NicolaisenG.PalmerK.FreihaF.: Utility of preoperative serum prostate specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology, 44(4): 519–524, 1994.
18.
FournierG.R.NarayanP.: Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer. Br. J. Urol., 72: 484–488, 1993.
19.
KramerS.A.SpahrJ.BrendlerG.B.GlennJ.F.PanlsonD.F.: Experience with Gleason histopathologic grading in prostatic cancer. J. Urol., 124: 223, 1980.
20.
PartinA.W.YooJ.CarterH.B.PearsonJ.D.ChanD.W.EpsteinJ.I.WalshP.C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110–114, 1993.
21.
RoachM.MarquezC.YuoH.S.NarayanP.ColemenL.NseyoU.O.NawabZ.CarrolP.R.: Predicting the risk of lymph node involvement using the pre treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int. J. Rad. Oncol. Biol. Phys.
